Adding Idelalisib to Bendamustine and Rituximab Improves PFS in CLL

Share this content:
Adding idelalisib to bendamustine plus rituximab significantly prolonged progression-free survival compared with chemoimmunotherapy alone.
Adding idelalisib to bendamustine plus rituximab significantly prolonged progression-free survival compared with chemoimmunotherapy alone.

Adding idelalisib to bendamustine plus rituximab significantly prolonged progression-free survival (PFS) compared with chemoimmunotherapy alone among patients with relapsed or refractory chronic lymphocytic leukemia (CLL), according to a study published in The Lancet Oncology.1

Novel therapies are needed to improve outcomes for patients in this setting. Researchers evaluated the efficacy and safety of adding idelalisib, a phosphoinositide-3-kinase δ inhibitor approved in combination with rituximab for relapsed CLL, to bendamustine plus rituximab.

For the international, double-blind, phase 3 trial (ClinicalTrials.gov Identifier: NCT01569295), investigators enrolled 416 adult patients with relapsed or refractory CLL who had measurable lymphadenopathy and had experienced disease progression within 36 months since last prior therapy.

Participants were randomly assigned 1:1 to receive a maximum of 6 cycles of bendamustine plus rituximab with either oral idelalisib or placebo given twice daily until disease progression or unacceptable toxicity.

Median follow-up was 14 months. Treatment with idelalisib significantly reduced the risk of progression or death by 67% compared with bendamustine plus rituximab alone (hazard ratio, 0.33; 95% CI, 0.25-0.44; P < .0001). Median progression-free survival was 20.8 months (95% CI, 16.6-26.4) in the idelalisib arm vs 11.1 months (95% CI, 8.9-11.1) in the placebo arm.

The most common grade 3 or worse adverse events among idelalisib-treated patients were neutropenia (60%) and febrile neutropenia (23%). The most frequent grade 3 or worse adverse events in the placebo group were neutropenia (47%) and thrombocytopenia (13%). Investigators also observed an increased risk of infection in the idelalisib arm.

Eleven percent of patients in the experimental group died due to treatment-emergent adverse events compared with 7% in the control arm.

RELATED: Nivolumab + Ibrutinib Active in Relapsed/Refractory CLL and Richter Transformation

The authors concluded that the findings demonstrate a significant improvement in progression-free survival with idelalisib in this population. Clinicians prescribing this drug combination should, however, carefully monitor for serious adverse events and infections associated with this regimen.

Reference

  1. Zelenetz AD, Barrientos JC, Brown JR, et al. Idelalisib or placebo in combination with bendamustine and rituximab in patients with relapsed or refractory chronic lymphocytic leukaemia: interim results from a phase 3, randomised, double-blind, placebo-controlled trial. Lancet Oncol. 2017 Jan 27. doi: 10.1016/S1470-2045(16)30671-4 [Epub ahead of print]

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs

Sign Up for Free e-newsletters